Objectives: Brexpiprazole is a new dopamine partial agonist antipsychotic in the same class as aripiprazole. This paper will briefly review brexpiprazole and compare it with aripiprazole. Conclusions: Brexpiprazole and aripiprazole are both partial agonists at dopamine D 2 , and serotonin 5-HT 1A and antagonists at serotonin 5-HT 2A and noradrenergic α 1B receptors. However, the two drugs are significantly different in potencies at various receptors; neurochemical profiles predict that brexpiprazole may be comparable with aripiprazole in its antipsychotic efficacy but may cause less akathisia, extrapyramidal side effects (EPS) and activation. In pivotal trials brexpiprazole demonstrated antipsychotic efficacy in short and long-term studies; it was also found to be an effective adjunct in patients with major depression resistant to antidepressants. Akathisia can occur early in treatment with brexpiprazole, as can minor weight gain and prolactin elevation. Indirect data extrapolations from pivotal studies suggest that brexpiprazole and aripiprazole have comparable efficacy but brexpiprazole may cause less akathisia. Like aripiprazole, brexpiprazole has been approved in the USA for use in schizophrenia and antidepressant-resistant depression. Although much more clinical experience is needed, brexpiprazole appears to be distinct from aripiprazole and a promising new 'metabolically-friendly' antipsychotic option for treatment of psychoses and mood disorders.
A ll antipsychotics are postsynaptic dopamine D 2 receptor antagonists. Positive psychotic symptoms are associated with dopamine overactivity in mesolimbic pathways while the negative symptoms of schizophrenia are associated with dopaminergic underactivity in the mesocortical pathways. Although this may be regarded as a simplistic formulation for the pathogenesis of schizophrenia and the mechanism of action of antipsychotic drugs, it generated considerable interest in partial dopamine agonists which could theoretically block dopamine overactivity in the midbrain while enhancing dopaminergic activity in the prefrontal cortex, simultaneously treating both positive and negative symptoms of schizophrenia. 1 For about a decade during the 1990s, studies with partial dopamine agonists could not demonstrate efficacy. The probable reason was that the drugs tested did not have the appropriate agonist:antagonist ratios. Then in 2002 Otsuka, a Japanese pharmaceutical company, developed aripiprazole which was the first effective partial dopamine agonist antipsychotic.
Experience with aripiprazole revealed that it had low propensity for both weight gain (only haloperidol, ziprasidone and lurasidone have lower weight gain risks) and metabolic syndrome in comparison with the early atypicals (clozapine, risperidone, olanzapine, and quetiapine). It was also associated with low cardiovascular risk and an actual tendency to lower prolactin concentrations compared with placebo. 2 Clinically, therapeutic efficacy was difficult to achieve and early in treatment some patients experienced troublesome activation and akathisia. Aripiprazole was subsequently found to be useful in the treatment of mood disorders, usually as an adjunct to antidepressants and mood stabilizers; 3 regulatory approval for use of aripiprazole as an adjunct to antidepressants in inadequately treated major depression was given in 2007.
The United States patent for aripiprazole expired in 2015 but in July of that year Otsuka received approval to market another partial dopamine agonist brexpiprazole, for the treatment of schizophrenia and as an adjunct to antidepressants in major depression. In May 2017, the Australian Therapeutic Goods Administration approved brexpiprazole for the treatment of schizophrenia in adults. 4 Brexpiprazole will soon be available to clinicians from the manufacturer through a familiarisation scheme. Brexpiprazole is not funded by the Pharmaceutical Benefits Scheme at this time.
Pharmacodynamics
Like aripiprazole, brexpiprazole is a dopamine D 2 receptor partial agonist. In dopamine-rich locations, it has been postulated that a partial agonist will act as a dopamine antagonist, which probably confers antipsychotic function in mesolimbic dopamine tracts. In dopaminepoor locations, a partial agonist will be a relative agonist, which may confer advantage in areas such as the pituitary (resulting in lower prolactin release) and mesocortical dopamine tracts associated with negative symptoms in schizophrenia.
The key issue for brexpiprazole is where it is located in relation to the 'sweet spot' of dopamine agonism-antagonism which determines the efficacy and tolerability characteristics. 1 Intrinsically brexpiprazole is a more potent dopamine antagonist than aripiprazole (though less potent than pure antagonists). 5 Theoretically brexpiprazole could be expected to cause less activation, nausea and akathisia than aripiprazole. 1, 6 Brexpiprazole is also a partial agonist at 5HT 1a receptors, which may mediate antidepressant properties. 5HT 1a activation may synergize with its potent 5HT 2a antagonism to increase neurite growth, which may have a role in antidepressant augmenting characteristics of brexpiprazole in depression. 7 Furthermore, brexpiprazole demonstrates antagonism at both 5HT 7 and noradrenergic α 1b/2c receptors, which may mediate mood and cognitive effects in schizophrenia, and postural hypotension with respect to α blockade. 6 Brexpiprazole has more potent binding at 5HT 2A , 5HT 1A , and α 1B receptors than aripiprazole. 1 Stronger serotonin 5-HT 2A receptor antagonism may confer lower propensity for EPS. 6 Brexpiprazole has low activity at histamine H 1 receptors and no anticholinergic activity. 1
Pharmacokinetics
Brexpiprazole is rapidly absorbed (peak in 4 hours), and highly bioavailable. Absorption is not affected by food and the drug is highly protein bound. The elimination half-life is 91 hours, so steady state will be reached in 19 days. Brexpiprazole is metabolised in the liver primarily by CYP 2D6 and 3A4. Inhibitors of 2D6 such as bupropion, paroxetine and fluoxetine will increase the blood levels of brexpiprazole as will grapefruit juice via CYP 3A4 inhibition, whereas CYP 3A4 inducers such as carbamazepine and St John's wort can be expected to reduce concentrations. Lower doses will be required by slow CYP2D6 metabolisers and vice versa. Age does not appear to affect pharmacokinetics, and concentrations are modestly increased by hepatic and renal impairment. 4 
Clinical evidence base
In acute schizophrenia, brexpiprazole demonstrated efficacy in two 6 week randomized, placebo-controlled registration studies in adults. In the first, 2 mg and 4 mg doses of brexpiprazole were superior to placebo but 0.25 mg was not. The overall rate of side effects was less for brexpiprazole than for placebo, and more patients discontinued placebo. The most common side effect was akathisia (2 mg: 4.4%; 4mg: 7.2%; placebo: 2.2%) and modest weight increase. No increase in prolactin or QT c interval was observed. 8 In the second trial, brexpiprazole 1 mg, 2 mg and 4 mg doses were compared with placebo. The 4 mg dose was superior to placebo, while the 1 mg and 2 mg doses were not. Headache, insomnia, agitation and weight gain were observed during treatment, and akathisia was higher in placebo than brexpiprazole while QT c and prolactin increases were not observed. 9 With respect to long-term studies, brexpiprazole 1-4mg was compared with placebo over 52 weeks. Brexpiprazole delayed time to relapse and was more effective than placebo, while the incidence of adverse effects with brexpiprazole was comparable with that of placebo. 10 An open study has compared brexpiprazole 3 mg with aripiprazole 15 mg per day over 6 weeks in acute schizophrenia. Similar improvement was observed between the two drugs but less akathisia was observed in brexpiprazole treated patients (9.4% versus 21.2% in aripiprazole). 11 A randomized double-blind study compared brexpiprazole (2-4 mg), placebo, or quetiapine extended release (400-800 mg) over 6 weeks in acute schizophrenia. Quetiapine demonstrated efficacy compared with placebo but brexpiprazole missed significance. 12 Overall, two studies support the efficacy of brexpiprazole as adjunct to antidepressants in major depression. Brexpiprazole doses of 2 and 3 mg were more effective than placebo, but caused more akathisia and weight gain. 13, 14 Further analysis of the findings from the two studies suggests brexpiprazole may be particularly useful in irritable or anxious depression. 15 Analysis of trial evidence suggests that the dose range of brexpiprazole for schizophrenia will be 2-4 mg; 5 mg caused a higher rate of akathisia. 16 By comparison, 2 mg is recommended for adjunctive treatment in major depression. 16 The maximum recommended dose of brexpiprazole is 4 mg per day. 4 
Discussion
Brexpiprazole and aripiprazole are distinct drugs which have significant differences in neurochemical characteristics with respect to degree of partial dopamine D 2 and 5HT 1A agonism, as well as 5HT 2A and α 2 antagonist properties. Both are partial dopamine agonists effective for schizophrenia, and both offer benefits among available antipsychotics with respect to their atypicality, metabolically-friendly profile, a tendency to lower prolactin and usefulness in mood disorders. Aripiprazole can cause problematic akathisia in early treatment. Brexpiprazole may be less prone to cause akathisia than aripiprazole. This would be a significant advantage, but experience with the drug is still at an early stage.
Like aripiprazole, brexpiprazole has minimal effects on QT c . Given the role of CYP2D6 in the metabolism of brexpiprazole, the drug is likely to have a broad dose range in clinical practice.
Are the differences between aripiprazole and brexpiprazole sufficiently substantial in clinical applications? While further clinical experience is clearly needed, at this point brexpiprazole appears to be a new antipsychotic option which offers some promise with respect to both efficacy and tolerability.
